This page shows the publications co-authored by Nancy Rigotti and A. Evins.
A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005 Jun; 25(3):218-25.
Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn. 2012; 8(2):117-125.
A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011 Oct; 31(5):597-602.
Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry. 2008 Nov; 69(11):1743-50.
Smoking cessation in patients with psychiatric disorders. Prim Care Companion J Clin Psychiatry. 2008; 10(1):52-8.
Smoking cessation in patients with psychiatric disorders. J Clin Psychiatry. 2007 Sep; 68(9):1404-10.
A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007 Aug; 27(4):380-6.
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry. 2005 Sep; 66(9):1184-90.
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004 Mar; 65(3):307-11; quiz 452-3.
A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001 Nov; 3(4):397-403.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.